Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Respiratory Medicine Unit, "Policlinico Foggia" University Hospital, Foggia, Italy.
Ir J Med Sci. 2023 Oct;192(5):2301-2303. doi: 10.1007/s11845-022-03241-1. Epub 2022 Dec 1.
The SARS-CoV-2 pandemic has prompted clinicians to develop an early and effective treatment of viral infections. To date, vaccines, monoclonal antibodies, and antivirals are the cornerstone of therapy for SARS-CoV-2. AIFA approved the prescription of molnupiravir on 30/12/2021. Molnupiravir is a prodrug that causes the accumulation of errors in the viral genome.
We prescribed molnupiravir to a total of 74 patients in a range between 26 and 96 years old and followed-up them for 30 days. 10 patients affected by idiopathic pulmonary fibrosis (IPF) were treated.
The follow-up showed that all of the treated patients presented a regression of symptoms. No patients were hospitalized and/or showed sequelae after the infection by SARS-CoV-2, even though the examined population was older and with more co-morbidities than other patients treated with different antivirals.
Molnupiravir is safe and well-tolerated by patients with high-risk of progression to severe COVID. No patients were hospitalized or showed sequelae, including all patients affected by IPF.
SARS-CoV-2 大流行促使临床医生开发出早期有效的病毒感染治疗方法。迄今为止，疫苗、单克隆抗体和抗病毒药物是治疗 SARS-CoV-2 的基石。AIFA 于 2021 年 12 月 30 日批准了莫努匹韦的处方。莫努匹韦是一种前药，可导致病毒基因组中错误的积累。
我们总共为 74 名年龄在 26 至 96 岁之间的患者开具了莫努匹韦，并对他们进行了 30 天的随访。其中有 10 名特发性肺纤维化 (IPF) 患者接受了治疗。
随访显示，所有接受治疗的患者症状均有所缓解。没有患者因 SARS-CoV-2 感染而住院和/或出现后遗症，尽管接受检查的人群比其他接受不同抗病毒药物治疗的患者年龄更大，合并症更多。
莫努匹韦对有进展为重症 COVID 高风险的患者安全且耐受良好。没有患者住院或出现后遗症，包括所有特发性肺纤维化患者。
